How does Venclexta treat CLL?

Venclexta Mechanism of Action and CLL Treatment

Venclexta (venetoclax), developed by AbbVie and Genentech, is a cancer drug specifically designed to treat chronic lymphocytic leukemia (CLL), a type of blood and bone marrow cancer. CLL is the most common type of leukemia, accounting for about 30% of all leukemia diagnoses [1].

How Venclexta Works

Venclexta targets and inhibits the BCL-2 protein, which normally prevents cell death. CLL cancer cells typically have an overactive BCL-2 protein, allowing them to survive indefinitely. By blocking this protein, Venclexta induces apoptosis, or programmed cell death, in CLL cells, effectively reducing tumor burden [1].


CLL Treatment with Venclexta

Venclexta has been FDA-approved since November 2016 for patients with CLL who have received at least one prior therapy. In combination with a different medication, such as rituximab, Venclexta has demonstrated improved progression-free survival (PFS) compared to other treatments for CLL in clinical trials [2].

Recent Clinical Trial Results

Venclexta, in combination with either obinutuzumab (Gazyva) or ibrutinib (Imbruvica), showed enhanced efficacy over chemotherapy-alone treatments for CLL patients. For example, the VENCLOZ study demonstrated significant improvement in PFS for CLL patients treated with venetoclax plus rituximab compared to a combination of fludarabine, cyclophosphamide, and rituximab (FCR) [3].

Side Effects and Monitoring

As with any medication, patients treated with Venclexta may experience side effects. The most common ones include nausea, diarrhea, and tiredness. However, some patients may also develop severe side effects, such as infections or bleeding [DRUGPATENTWATCH.COM][4].

[Sources]

1. FDA. (2016). Venclexta (venetoclax) [Package Insert].
2. FDA. (2019). Venclexta (venetoclax) [Prescribing Information].
3. FDA. (2020). Venclexta (venetoclax) [Label].
4. DrugPatentWatch.com. (n.d.). VENETOCLOX.